Drug class

Ophthalmic Carbonic Anhydrase Inhibitors

Ophthalmic carbonic anhydrase inhibitors are a class of topical ocular medications, including dorzolamide and brinzolamide, used to reduce intraocular pressure. Read more about Ophthalmic Carbonic Anhydrase Inhibitors

47 drugs in this class 22 manufacturers

Related classes & indications

Iron Chelating AgentsOther therapeutic classes · 45 prescription drugs Phosphodiesterase-4 (PDE4) inhibitorsOther therapeutic classes · 20 prescription drugs Open Angle GlaucomaTop indication · 295 prescription drugs

Showing 1–9 of 47 drugs

Sort

DORZOLAMIDE-TIMOLOL (dorzolamide HCl/timolol maleate)

OPHTHALMIC BETA-BLOCKERS · OCULAR HYPERTENSION ·+1

SANDOZ

DORZOLAMIDE HCL

OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS · OCULAR HYPERTENSION ·+1

SANDOZ

DORZOLAMIDE (dorzolamide HCl)

OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS · OCULAR HYPERTENSION ·+1

BAUSCH & LOMB P

DORZOLAMIDE-TIMOLOL (dorzolamide HCl/timolol maleate)

OPHTHALMIC BETA-BLOCKERS · OCULAR HYPERTENSION ·+1

BAUSCH & LOMB P

SIMBRINZA (brinzolamide/brimonidine tartrate)

OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS · OCULAR HYPERTENSION ·+1

Alcon Laboratories

DORZOLAMIDE (dorzolamide HCl/PF)

OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS

IMPRIMIS NJOF,

DORZOLAMIDE-TIMOLOL (dorzolamide HCl/timolol maleate/PF)

OPHTHALMIC BETA-BLOCKERS · OCULAR HYPERTENSION ·+1

AUROBINDO PHARM

BRIMONIDINE-DORZOLAMIDE (brimonidine tartrate/dorzolamide HCl/PF)

OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS

IMPRIMIS NJOF,

TIMOLOL-BRIMONIDIN-DORZOLAMIDE (timolol maleate/brimonidine tartrate/dorzolamide HCl/PF)

OPHTHALMIC BETA-BLOCKERS

IMPRIMIS NJOF,

Filter & compare in the drug finder → Opens the drug finder with Ophthalmic Carbonic Anhydrase Inhibitors preselected. Add indication or manufacturer filters there.

About Ophthalmic Carbonic Anhydrase Inhibitors.

Ophthalmic carbonic anhydrase inhibitors are a class of topical ocular medications, including dorzolamide and brinzolamide, used to reduce intraocular pressure.

They function by inhibiting the enzyme carbonic anhydrase within the ciliary body epithelium, which slows bicarbonate ion synthesis and subsequently decreases aqueous humor production and fluid transport.

Therapeutically, these agents are primarily indicated for the management of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, either as monotherapy or as adjunctive therapy with other intraocular pressure-lowering agents.

By delivering targeted local enzyme inhibition, they minimize many of the systemic adverse effects traditionally associated with oral carbonic anhydrase inhibitors while mitigating the risk of progressive glaucomatous optic nerve damage.

nih.gov
Ophthalmic carbonic anhydrase inhibitors are a class of topical ocular medications, including dorzolamide and brinzolamide, used to reduce intraocular pressure Therapeutically, these agents are primarily indicated for the management of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, either as monotherapy or as adjunctive therapy with other intraocular pressure-lowering agents
nih.gov
Ophthalmic carbonic anhydrase inhibitors are a class of topical ocular medications, including dorzolamide and brinzolamide, used to reduce intraocular pressure Therapeutically, these agents are primarily indicated for the management of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, either as monotherapy or as adjunctive therapy with other intraocular pressure-lowering agents
nih.gov
Ophthalmic carbonic anhydrase inhibitors are a class of topical ocular medications, including dorzolamide and brinzolamide, used to reduce intraocular pressure
fda.gov
They function by inhibiting the enzyme carbonic anhydrase within the ciliary body epithelium, which slows bicarbonate ion synthesis and subsequently decreases aqueous humor production and fluid transport
pharmacytimes.com
They function by inhibiting the enzyme carbonic anhydrase within the ciliary body epithelium, which slows bicarbonate ion synthesis and subsequently decreases aqueous humor production and fluid transport
nih.gov
They function by inhibiting the enzyme carbonic anhydrase within the ciliary body epithelium, which slows bicarbonate ion synthesis and subsequently decreases aqueous humor production and fluid transport
nih.gov
Therapeutically, these agents are primarily indicated for the management of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, either as monotherapy or as adjunctive therapy with other intraocular pressure-lowering agents
nih.gov
By delivering targeted local enzyme inhibition, they minimize many of the systemic adverse effects traditionally associated with oral carbonic anhydrase inhibitors while mitigating the risk of progressive glaucomatous optic nerve damage
nih.gov
By delivering targeted local enzyme inhibition, they minimize many of the systemic adverse effects traditionally associated with oral carbonic anhydrase inhibitors while mitigating the risk of progressive glaucomatous optic nerve damage

Ophthalmic Carbonic Anhydrase Inhibitors

Drugs in Ophthalmic Carbonic Anhydrase Inhibitors

About Ophthalmic Carbonic Anhydrase Inhibitors.